Method evidence record
Target-Mediated Drug Disposition
Target-mediated drug disposition (TMDD) is a mechanistic framework describing nonlinear pharmacokinetics arising from drug binding to a target receptor or protein. Developed by Mager and Jusko in 2001, TMDD explains saturable clearance, dose-dependent half-lives, and time-dependent changes in plasma concentrations observed with protein therapeutics and some small-molecule drugs.
Source record
Citations copied verbatim from the method’s source record. No claim-level verification is inferred from them.
Target-Mediated Drug Disposition (TMDD)
Taxonomic method record · process-pipeline / pharmacology
- Mager, D. E., & Jusko, W. J. (2001). General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics, 28(6), 507-532. · DOI 10.1023/A:1014414520282
- Levy, G. (2004). Carrier-mediated active transport: pharmacokinetic consequences and examples in humans. Clinical Pharmacokinetics, 37(6), 429-445. · URL
Curated claims
Claims persisted in the evidence ledger, each with its own assessment.
No curated claims yet
This view does not invent a claim assessment when the ledger has none.
Related methods
Generated from the method graph and shown as machine-suggested relations — no evidence claim is inferred.